Quintiles Transitional Holdings Inc. (NYSE:Q) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage currently has a $93.42 price objective on the medical research company’s stock, up from their prior price objective of $70.10. William Blair’s target price would suggest a potential upside of 3.32% from the company’s current price. William Blair also issued estimates for Quintiles Transitional Holdings’ Q4 2017 earnings at $1.34 EPS, FY2017 earnings at $4.57 EPS, FY2018 earnings at $5.31 EPS and FY2019 earnings at $6.03 EPS.

A number of other research firms have also issued reports on Q. Zacks Investment Research lowered shares of Quintiles Transitional Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, April 26th. Robert W. Baird upgraded shares of Quintiles Transitional Holdings from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $76.00 to $93.00 in a report on Friday, July 7th. Jefferies Group LLC boosted their price target on shares of Quintiles Transitional Holdings from $78.00 to $81.00 and gave the company a “hold” rating in a report on Monday, May 15th. Evercore ISI restated an “in-line” rating and set a $88.50 price target (up previously from $84.00) on shares of Quintiles Transitional Holdings in a report on Thursday, May 4th. Finally, Credit Suisse Group restated an “outperform” rating and set a $96.00 price target (up previously from $94.00) on shares of Quintiles Transitional Holdings in a report on Tuesday, June 6th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $89.88.

Shares of Quintiles Transitional Holdings (NYSE:Q) traded down 0.75% on Friday, reaching $90.42. 1,263,883 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $89.50 and its 200-day moving average price is $82.85. The company has a market capitalization of $19.90 billion, a P/E ratio of 200.04 and a beta of 0.64. Quintiles Transitional Holdings has a 1-year low of $70.10 and a 1-year high of $93.53.

Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.04. The company had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.96 billion. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 15.68%. The business’s revenue for the quarter was up 68.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 EPS. Analysts anticipate that Quintiles Transitional Holdings will post $4.55 EPS for the current fiscal year.

Quintiles Transitional Holdings announced that its board has initiated a stock buyback program on Wednesday, May 24th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 5.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: “Quintiles Transitional Holdings Inc. (Q) Upgraded by William Blair to Outperform” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/06/quintiles-transitional-holdings-inc-q-upgraded-by-william-blair-to-outperform.html.

In other Quintiles Transitional Holdings news, major shareholder Cpp Investment Board Private H sold 7,131,165 shares of the stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $84.01, for a total value of $599,089,171.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dennis B. Ph D. Gillings sold 860,000 shares of the stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $84.01, for a total transaction of $72,248,600.00. Following the completion of the sale, the director now directly owns 10,002,230 shares of the company’s stock, valued at $840,287,342.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,758,400 shares of company stock valued at $735,783,985. 6.40% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Quintiles Transitional Holdings by 4,217.1% in the first quarter. BlackRock Inc. now owns 7,098,723 shares of the medical research company’s stock worth $571,660,000 after buying an additional 6,934,290 shares during the period. Gulf International Bank UK Ltd increased its stake in shares of Quintiles Transitional Holdings by 1.1% in the first quarter. Gulf International Bank UK Ltd now owns 49,056 shares of the medical research company’s stock worth $3,950,000 after buying an additional 545 shares during the period. WCM Investment Management CA increased its stake in shares of Quintiles Transitional Holdings by 0.3% in the first quarter. WCM Investment Management CA now owns 558,238 shares of the medical research company’s stock worth $44,955,000 after buying an additional 1,803 shares during the period. Creative Planning increased its stake in shares of Quintiles Transitional Holdings by 35.4% in the first quarter. Creative Planning now owns 4,482 shares of the medical research company’s stock worth $361,000 after buying an additional 1,172 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its stake in shares of Quintiles Transitional Holdings by 31.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 22,313 shares of the medical research company’s stock worth $1,797,000 after buying an additional 5,340 shares during the period. 92.47% of the stock is owned by hedge funds and other institutional investors.

About Quintiles Transitional Holdings

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.